Pacific Biosciences Of California (PACB) Other Accumulated Expenses (2011 - 2026)

Pacific Biosciences Of California has reported Other Accumulated Expenses for 16 years, with the latest figure at $1.8 million in Q2 2026.

• On a quarterly basis, Other Accumulated Expenses fell 31.1% year-over-year to $1.8 million in Q2 2026; TTM through Jun 2026 was $1.8 million, a 31.1% decrease from a year earlier, with the FY2025 full-year figure at $2.0 million, down 37.0% from the prior year.
• Other Accumulated Expenses was $1.8 million for Q2 2026 at Pacific Biosciences Of California, up from $1.2 million in the prior quarter.
• The five-year high for Other Accumulated Expenses was $8.3 million in Q4 2023, with the low at $783000.0 in Q3 2024.
• Average Other Accumulated Expenses over 5 years is $4.1 million, with a median of $3.9 million recorded in 2022.
• The sharpest annual moves came in 2022 and 2024: Other Accumulated Expenses soared 103.31% in 2022, then tumbled 84.85% in 2024.
• Over 5 years, Other Accumulated Expenses stood at $7.2 million in 2022, then advanced by 15.11% to $8.3 million in 2023, then sank by 61.28% to $3.2 million in 2024, then sank by 37.0% to $2.0 million in 2025, then decreased by 12.06% to $1.8 million in 2026.
• The last three Other Accumulated Expenses figures came in at $1.8 million (Q2 2026), $1.2 million (Q1 2026), and $2.0 million (Q4 2025), per Business Quant data.